Monthly Prescribing Reference

Enflonsia Approved for RSV Disease Prevention in Infants

Credit: Merck Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody. The product is administered as a single intramuscular injection using the same dose ...

Florida Department of Health sees increase in RSV in Northeast Florida

Respiratory Syncytial Virus is increasing in Northeast Florida, according to the Florida Department of Health.
The New England Journal of Medicine

Clesrovimab for Prevention of RSV Disease in Healthy Infants

Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein. Data regarding the safety and efficacy of clesrovimab in ...
Seeking Alpha

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory ...
Seeking Alpha

ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 ...

ENFLONSIA is the first and only RSV preventive option for administration to infants using the same dose regardless of weight Ordering will begin in July, with shipments delivered before the start of ...
The New England Journal of Medicine

Clesrovimab in Infants and Children at Increased Risk for Severe RSV Disease

Palivizumab-eligible infants under the age of 1 year who had been born prematurely (gestational age, ≤35 weeks) or who had chronic lung disease of prematurity or hemodynamically significant congenital ...